abstractsPoster session 1: Clinical studiesP1.01 - A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)
Poster session 1: Clinical studies
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.